SE0201939D0 - New combination - Google Patents

New combination

Info

Publication number
SE0201939D0
SE0201939D0 SE0201939A SE0201939A SE0201939D0 SE 0201939 D0 SE0201939 D0 SE 0201939D0 SE 0201939 A SE0201939 A SE 0201939A SE 0201939 A SE0201939 A SE 0201939A SE 0201939 D0 SE0201939 D0 SE 0201939D0
Authority
SE
Sweden
Prior art keywords
new combination
relates
disease
reflux
thrive
Prior art date
Application number
SE0201939A
Other languages
Swedish (sv)
Inventor
Anders Lehmann
Michael Wrangstadh
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201939A priority Critical patent/SE0201939D0/en
Publication of SE0201939D0 publication Critical patent/SE0201939D0/en
Priority to ARP030102094A priority patent/AR040202A1/en
Priority to AU2003239025A priority patent/AU2003239025A1/en
Priority to PCT/SE2003/001007 priority patent/WO2004000855A1/en
Priority to TW092116263A priority patent/TW200400826A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/04—Sulfinic acids; Esters thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The present invention relates to a medicament comprising, separately or together, (i) at least one acid secretion inhibiting agent; and (ii) at least one reflux inhibitor. A further aspect of the invention relates to methods of treatment of gastro-esophageal reflux disease, regurgitation, asthma, failure to thrive and lung disease.
SE0201939A 2002-06-20 2002-06-20 New combination SE0201939D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE0201939A SE0201939D0 (en) 2002-06-20 2002-06-20 New combination
ARP030102094A AR040202A1 (en) 2002-06-20 2003-06-11 COMBINATION OF AN INHIBITING AGENT OF THE ACID SECRETION AND A REFLUX INHIBITOR FOR THE TREATMENT OF GERD
AU2003239025A AU2003239025A1 (en) 2002-06-20 2003-06-16 Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd
PCT/SE2003/001007 WO2004000855A1 (en) 2002-06-20 2003-06-16 Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd
TW092116263A TW200400826A (en) 2002-06-20 2003-06-16 Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of GERD

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201939A SE0201939D0 (en) 2002-06-20 2002-06-20 New combination

Publications (1)

Publication Number Publication Date
SE0201939D0 true SE0201939D0 (en) 2002-06-20

Family

ID=20288297

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201939A SE0201939D0 (en) 2002-06-20 2002-06-20 New combination

Country Status (5)

Country Link
AR (1) AR040202A1 (en)
AU (1) AU2003239025A1 (en)
SE (1) SE0201939D0 (en)
TW (1) TW200400826A (en)
WO (1) WO2004000855A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
SE0402462D0 (en) * 2004-10-08 2004-10-08 Astrazeneca Ab New process
WO2006050472A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
WO2008033572A1 (en) 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2009014490A1 (en) * 2007-07-25 2009-01-29 Astrazeneca Ab Combination of (3-amino-2-fluoropropyl)phosphinic acid and omeprazole for treating tlesr, gerd, and nerd

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (en) * 1996-09-18 1996-09-18 Astra Ab Medical use
SE9801526D0 (en) * 1998-04-29 1998-04-29 Astra Ab New compounds
SE9904507D0 (en) * 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904508D0 (en) * 1999-12-09 1999-12-09 Astra Ab New compounds

Also Published As

Publication number Publication date
WO2004000855A1 (en) 2003-12-31
TW200400826A (en) 2004-01-16
AU2003239025A1 (en) 2004-01-06
AR040202A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
SE0301888D0 (en) New use VII
SE0301882D0 (en) New use I
SE0301886D0 (en) New use V
ATE408601T1 (en) FREDERICAMYCIN DERIVATIVES
NO20065847L (en) Diphenylimidazopyrimidines and imidazolamines as inhibitors of B-secretase
NO20073831L (en) Medications for the treatment or prevention of fibrotic diseases
DE60215787D1 (en) TREATMENT OF TYPE II DIABETES WITH DIPEPTIDYL PEPTIDASE IV INHIBITORS
SE0201940D0 (en) New combination II
CY1110669T1 (en) USE OF SULFAMIDI-CONTAINED HYDRO-CYCLOTIC PRODUCERS OF SULFAMIDE
TNSN06138A1 (en) INHIBITORS OF THE MUTANT FORM OF KIT
EA200600223A1 (en) SUBSTITUTED 2-AMINOTHETRALINES FOR THE TREATMENT OF DEPRESSION
EA200701181A1 (en) MEDICINES INTENDED FOR THE TREATMENT OR PREVENTION OF FIBROUS DISEASES
DK1458393T3 (en) Substituted diketopiperazines as oxytocin antagonists
TW200505829A (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
HRP20050579B1 (en) New synergistic combination comprising roflumilast and formoterol
SE0201939D0 (en) New combination
DE50310038D1 (en) INGREDIENTS OF UROKINASE, THEIR PREPARATION AND USE
SE0301883D0 (en) New use II
DK1664044T3 (en) Monohydrated sodium salt of S-tenatoprazole and its use in the form of a proton pump inhibitor
NO20063790L (en) Substituted azetidine compositions as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
CO5690571A2 (en) SYNERGIC COMBINATION INCLUDING ROFLUMILAS AND (R, R) -FORMOTEROL
SE0002739D0 (en) New use
SE0200198D0 (en) New use
ATE444754T1 (en) USE OF TYROSINKINASE INHIBITORS TO TREAT INFLAMMATORY PROCESSES
SE0301885D0 (en) New use IV